<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 316 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page315.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=316">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 316 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 316</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=316"><img src="../thumb/316.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Anti-Microbials - 18.12                                                        2020-04 / 279
       phataem., dyspn., abdom. discomf., ren.insuffic., ren.fail., sweat.   Hypersens., immune reconstitut.syndr., vomit., flatul., upper abdom.  pneum., dyspn., osteomalac., fev., sweat., lumb.spine/hip & both
       Less freq: Angioed., hepat.steatos., hypokalaem., suicid. ideat./   pain. Freq.unknown: Abdom.pain/ discomf., hepatit.  arms BMD decr. from baseline
       attempt., neutropen., anaem., thrombocytopen., lact.acidos./sev.  Warnings and special precautions: Not indic. for treatm.of   Special precautions: Monit.hepat.funct.for sev. mnths.in pts.
       hepatomegaly with steatos.incl fatal.cases esp.women, sev.ac. ex-  chron.hepatit.B infect., safety & effic. not est.in HBV & HIV co-  co-infect.with HIV & HBV who discont. ther., init.anti-hepatit.B
       acerbat. of hepatit.B aft.discont, lipodystrophy, late onset neurologic.  infects., monit.hepat. funct. for sev.mnths.in pts.co-infect.with HIV   ther.if appropr., obesity & prolong.nucleoside use poss.risk fact.
       disord.in childr.expos.in utero, pancreatit., incr.AST/ALT, rhabdomy-  & HBV who discont.ther.& appropr.init.of anti-hepatit. B ther.poss.  for lact.acidos., liv.dis.risk fact., discont.if find. suggest. lact.aci-
       olys., decr. bone miner.dens., osteopen., fract., allerg. react., hepatit.,   necess., metabol.abnormalit., eval. for signs of fat redistrib., monit.  dos./hepatotoxic., test for chron. hepatit.B bef.init.ther., determ.
       incr.amylase, myopathy, osteomalac., hypersens., immune recon-  fast.ser. lipids & bld.gluc.levs., CV risk assessm.with evid. of lipod-  creatin.clear.bef. init.ther., avoid with concom./rec.nephrotox.
       stitut. syndr. Freq.unknown: Pure red cell aplas., Fanconi syndr.,   ystrophy, immune reconstit.inflam.syndr., pts. to seek med.advice if   agents, immed.risk vs.benefit eval.of cont.ther. when ser.psych.
       autoimmun.disords., incr.weigh., osteonecros., incr.bld lipids/gluc.  exper.joint pain/aches/ stiffn./ movem.diffic.as osteonecros.poss.,   sympts.exper., bedt.dos.poss. improv.tol.of CNS effs., poss.ad-
       Warnings and special precautions: Not indic. for treatm.of   opportunist. infects.& other HIV complicat.may still devel., ARV ther.  dit.CNS effs.with concom.alcoh/psychoact.meds., seiz.hist., dis-
       chron.hepatit.B infect., safety & effic. not est.in HBV & HIV co-  will not prev.risk of transmiss. through sex.cont.& bld.contamin.&   cont. if pancreatit.suspect.till diagn.excl., do not admin. concom.
       infects., monit.hepat. funct. for sev.mnths. in pts.co-infect.with   appropr. precaut. to contin., discont.in clinic./lab.find. suggest. lact.  saquinavir as sole protease inhibit., rash report.with efavirenz &
       HIV & HBV who discont.ther.& appropr.init.of anti-hepatit. B ther.  acidos./hepatotox., pts.with known risk for liv.dis, pts.with hepa-  clarithromycin theref. consid.alt., barr.contracept.in addit.to OC’s
       poss.necess., metabol.abnormalit., eval. for signs of fat redistribut.,   tomegaly/hepatit/ other risk facts.for liv.dis./hepat.steatos., pts.  recomm., monit.IV drug users for poss.withdr.when using metha-
       monit.fast. ser. lipids & bld.gluc.levs., CV risk assessm.with evid.   co-infect. with hepatit.C & treat.with alpha interferon & ribavarin,   done, high dos.co-trimoxaz.in PCP & toxoplasmos.to be avoid., tera-
       of lipodystrophy, pts.to seek med.advice if exper. joint pain/aches/  eff.on clinic.progress.of HIV-1 not demonst., investig.childr.expos.  togenic.with efavirenz, cont.adeq.contracept.x12 wks.aft. discont.,
       stiffn./movem.diffic.as osteonecros. poss., opportunist.infects.&   in utero to nucleoside & nucleotide analog.for poss. mitochondr.   tenofov.secret.in breast milk, take miss. dos. when remembered
       other HIV complicat. may still devel., ARV ther.will not prev. risk   dysfunct.in case of relev.S&S, discont. ther. until pancreatit.excl.in   unless there is less than 12 hrs.bef.next dos., concom.didanosine
       of transmiss.through sex.cont.& bld.contamin. & appropr.precaut.  cases of N&V/abdom. pain/ elev.biochem.mark., ren.funct.impairm.,   not recomm., do not admin.concom atazanavir without ritonav.,
       to contin., discont.in clinic./lab. find. suggest.lact.acidos./hepato-  safety & effic.not est.in signific.underly.liv. disords., monit.liv.funct.  discont.ther.with sev.skin rash assoc. with blister./desquamat./
       tox., pts.with known risk for liv.dis, pts.with hepatomegaly/ hep-  with pre-exist.liv.dysfunct., cons. ther.interrupt./discont.if evid.of   mucos.involvem.& fev., consid.discont.other antiretrovir.to avoid
       atit/ other risk facts.for liv.dis./hepat.steatos., pts. co-infect.with   worsen.liv. dis., monit.ren.funct.bef.init.ther & periodic. thereaft.   drug resist.virus develop.if efavirenz discont., eval.risk vs.benef.
                                          st
       hepatit.C & treat.with alpha interferon & ribavarin, eff.on clinic.  (4 wkly dur.1  yr.of treatm. & 3 mnthly theraft.), avoid combin.with   of cont.ther.if ser.transaminase.lev. persist. 5x&gt;ULN, monit.BMD
       progress.of HIV-1 not demonst., investig.childr.expos.in utero to   concurr./recent nephrotox. meds., concom.meds.secret.by same ren.   in pts.with patholog. bone fract. hist./at risk of osteopen., Ca &
       nucleoside & nucleotide analog.for poss. mitochondr. dysfunct.  pathway, avoid in antiretrov.exper.pts.with HIV-1 harbour.K65R mu-  vit.D supplementat.poss benefic., elderly, lact.intol.
       in case of relev.S&S, discont. ther. until pancreatit.excl.in cases   tat., bone monit.with patholog. bone fract.hist./osteopen.risk, Ca &   Drug interactions: Ser.conc.of drugs elimin.by act.tubul.secret.
       of N&V/abdom. pain/ elev.biochem.mark., ren.funct.impairm.,   vit.D supplement. poss.benefic., incr.risk for sev./fat. hepat. adverse   may incr., plasma conc.of other compds. that are CYP3A4 substrat.
       safety & effic.not est.in signific.underly. liv. disords., monit.liv.funct.  effs.in chron.hepatit.B or C co-infect., ref.to PI of concom.hepat.B or   poss.decr., meds. induc.CYP3A4 activ.(eg.phenobarbit./ rifampic. &
       with pre-exist.liv.dysfunct., cons. ther.interrupt./discont.if evid.of   C meds., exacerb. of hepatit.dur/aft.treatm., liv.flares esp. in decom-  rifabutin) incr.clear., indinavir AUC & Ctrough decr., incr.clinic.adverse
       worsen. liv. dis., monit.ren.funct.bef.init.ther & periodic. thereaft.   pensat.liv.dis., limit.data in elderly &gt; 65 yrs., discont.ther.immed.if any   reacts.with ritonavir, saquinavir AUC & C max decr., rifampicin decr.
       (4 wkly dur.1  yr.of treatm. & 3 mnthly theraft.), avoid combin.with   hypersens.react. susp./ occurs.& init.appropr.ther., poss.impact.on   efavirenz AUC & C max  efavirenz has signific.eff.on clarithromyc.
             st
       concurr./recent nephrotox. meds., concom.meds.secret.by same   glycaem.contr.in diabet.pts., avoid in wom.plan. pregn., reproduct.  pharmacokinet., ethinyl oestrad.AUC incr., methadone plasma conc.
       ren. pathway, avoid in antiretrov.exper.pts.with HIV-1 harbour.K65R   toxic.report., init.pregn.test in women of childbear.potent./periodic.  decr., reduc. efavirenz conc.with St John’s Wort expect., atazanavir./
       mutat., bone monit. with patholog. bone fract.hist./osteopen.risk,   dur.treatm.& when pregn.suspect., lamivudine/tenofov.excret. in   lopinavir.&ritonavir combinat.and saquinavir & ritonavir combinat.
       Ca & vit.D supplement. poss.benefic., incr.risk for sev./fat. hepat.   breast milk, monit.with concom.co-trimoxazole, concom. tacrolimus   incr.tenofovir conc., tenofovir incr.abacavir/saquinavir & ritonavir
       adverse effs.in chron.hepatit.B or C co-infect., ref.to PI of concom.  as ren funct poss.affect., concom. ETR not recomm.unless receiv.  combinat. C max, tenofovir decr. atazanavir/atazanavir & ritonavir
       hepat.B or C meds., immune reconstit.inflam.syndr., exacerb.of   concom. ATV + RTV/ LPV + RTV or DRV + RTV, do not admin. concom.  combinat./ indinav.& lamivudine pharmacokinet.paramet., signific.
       hepatit. dur/ aft.treatm., limit.data in elderly &gt; 65 yrs., discont.   with emtricitabine/other cytidine analogues., admin.2 hrs.bef./6 hrs.  clinic.change in didanosine pharmacokinet. with tenofovir., potent.
       ther.immed.if any hypersens.react.susp./ occurs.& init.appropr.ther.,   aft. polyval. cation-cont.antacids, admin.2 hrs.bef./6 hrs. aft. Ca/Fe   addit.CNS effs.with alcoh.& psychoact.meds.
       avoid in wom.plan. pregn., reproduct.toxic.report., init.pregn.test   supplem, contains mannit.which may have laxat.eff., lactose intol.
       in women of childbear.potent./periodic.dur.treatm.& when pregn.  Interactions: Isoniazid conc.poss incr.by dolutergravir, lamivudine   TENCITAB, (Aspen Pharmacare: Pharma) Pharmacare [P/S]
       suspect., lamivudine excret. in breast milk, monit.with concom.co-  poss.inhib.intracellul. phosphorylat. of zalcitabine/cladribine, tri-  Emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg
       trimoxazole, concom. tacrolimus as ren funct poss.affect., concom.   methoprim incr.lamivudine plasma lev., interacts. poss.with hepatit.C   Indications: In combinat.with other antiretrovir.in adults with HIV-1
       ETR not recomm.unless receiv.concom.ATV + RTV/ LPV + RTV or   antivir.meds., lamivudine incr. expos.& peak.plasma lev.of zidovu-  infect., pre-expos. prophylax. (PrEP) in combinat.with safer sex prac-
       DRV + RTV, do not admin.concom.with emtricitabine/other cytidine   dine, conc.of tenofovir/concom.med incr. with concom.drugs elim.  tic.in prov. HIV-1 uninfect.adults to red.risk of sexual.acquir. HIV-1 in
       analogues., avoid chron. co-admin.of sorbitol/other osmot.act.po-  by glomerul.& act.tubul. secret., tenofov.ser.conc.incr.by agents decr.  pts.at high risk prov.complianc.monit.
       ly-or monosaccharide acohols, admin.2 hrs.bef./6 hrs. aft. polyval.  ren. funct., C max & AUC of didanosine incr.with multi. dos. of teno-  (S4) TABS, 43/20.2.8/0130
       cation-cont.antacids, admin.2 hrs.bef./ 6 hrs. aft.Ca/Fe supplem.  fovir, atazanavir incr. tenofovir C max/AUC/C min., lopinavir + ritonavir   715579-001: 30, R456,30
       Interactions: Isoniazid conc.poss incr.by dolutergravir, lamivu-  incr.tenofovir AUC/C min., indinavir incr.tenofovir C max, tenofovir incr.   Dosage: 1 tab.once dly.without regard to food.
       dine poss.inhib. intracellul. phosphorylat. of zalcitabine/cladrib-  C max of abacavir/indinavir, tenofovir incr. C max/AUC/Cmin of ataza-  Contraindications: Safety & effic.not est.in hepatit. B vir.& HIV co-
       ine, trimethoprim incr.lamivudine plasma lev., interacts. poss.with   navir, poss.incr. metformin/ dofetilide/pilsicainide plasma conc.   infects., pregn.& lactat., mod.to sev.ren.impairm., creatin. clear. &lt;
       hepatit.C antivir.meds., lamivudine incr. expos.& peak.plasma lev.  with dolutegravir., poss.decr.dolutegravir conc. with oxcarbazepine/  60 ml/ min when used for PrEP & &lt; 50 ml/min when used for treatm.
       of zidovudine, conc.of tenofovir/concom.med incr. with concom.  phenytoin/phenobarb./ carbamazepine/ St John’s Wort though no   of HIV-1., concom.drugs contain lamivudine/tenofovir/emtricitabine,
       drugs elim.by glomerul.& act.tubul. secret., tenofov.ser.conc.incr.by   studies, reduc. dolutegravir plasma conc.with etravirine/ efavirenz/   safety & effic.in paed.pts.not est., PrEP in indiv.not fully committ.to
       agents decr.ren. funct., C max & AUC of didanosine incr., atazanavir   nevirapine/rifampicin, incr.dolutegravir plasma conc.with atazanavir/  treatm.compl./indiv. with unknown/posit. HIV-1 status.
       incr. tenofovir C max/AUC/C min., lopinavir + ritonavir/ darunavir + ri-  atazanavir + ritonavir, decr.dolutegravir conc.with tipranavir + ritona-  Side effects: Lactic.acidos.& sev.hepatomegaly with steatos.incl.
       tonavir incr.tenofovir AUC/C min., indinavir incr.tenofovir C max, teno-  vir/ fosamprenavir + ritonavir/darunavir + ritonavir   fatal., sev.ac.exacerbat.of hepatit. B aft.discontinuat., ac.ren.fail.&
       fovir incr. C max of abacavir/indinavir, tenofovir incr. C max/AUC/Cmin   Fanconi syndr., neutropen., proxim.tubulopathy, ac.tubul. necros.,
       of atazanavir, sorbitol decr.lamivudine C max & AUC, poss. incr.met-  TENARENZ, (Aspen Pharmacare) Pharmacare, [P/S]  allerg.reacts.incl.angioed., hyperglycaem., hypertriglyceridaem.,
       formin/dofetilide/pilsicainide plasma conc. with dolutegravir., poss.  Tenofovir disoproxil fumarate 300 mg, efavirenz 600 mg, lamivu-  hypophosphataem., hypokalaem, insomn., abnorm.dreams, diz-
       decr.dolutegravir conc. with oxcarbazepine/ phenytoin/phenobarb./   dine 300 mg.  zin., headache, GI disturbs., rais.liv.enzymes, hepatit., hepat.stea-
       carbamazepine/ St John’s Wort though no studies, reduc. dolute-  Indications: HIV-1 infect.adults over 18 yrs.who have been   tos., rash, prurit., urticar., skin discolourat., myopathy, creatine ki-
       gravir plasma conc.with etravine/ efavirenz/ nevirapine/rifampicin,   treat.& stabil.on a combinat.of the above separate formulat.at   nase elev., osteomalac., osteonecros., nephrogen. diab. insipid.,
       incr.dolutegravir plasma conc.with atazanavir/ telaprevir/atazana-  simil.dosages.  polyur., interstit.nephrit., pain, asthen., BMD decr., body fat redis-
       vir + rotonavir, decr.dolutegravir conc.with tipranavir + ritonavir/   (S4) TABS, 44/20.2.8/1051  tribut./accumulat.
       fosamprenavir + ritonavir     717780-001: 30, R374,58      Warnings and special precautions: Monit. hepat.funct.for sev.
                                     Dosage: Adults: 1 tab.once dly.on empty stomach. Bedt.dos.may
       TEMIV, Emcure [P/S]           improv.CNS sympt. tolerabil.  mnths.if discont.& pts.co-infect. with HIV & HBV, hepatitis C co-
                                                                  infect., not recomm.as part of triple nucleoside regim., opportunist.
       Lamivudine 300 mg, tenofovir disoproxil fumarate 300 mg, dolute-  Contraindications: Safety & effic.not est.in co-infect.HBV & HIV   infects.& HIV complicat.may contin., prev.of risk of HIV transmiss.
       gravir sod.equiv.to dolutegravir 50 mg   pts., pregn. & lactat., mod-sev. ren.impairm., mod to sev.uncontrol.  not proven, obesity & prolong.nucleoside use poss.risk fact.for lact.
       Indications: Treatm.of HIV infect.adults ≥ 18 yrs.  ren.fail., concom. meds/combinat.contain.Tenarenz act.ingred., con-  acidos., liv.dis.risk fact., pancreatit., mitochondr. dysfunct., discont.if
       (S4) TABS, 53/20.2.8/0089     com.adefovir dipivoxil, concom. astemizole/bepridil/cisapride/mida-  find.suggest.lact.acidos./ hepatotoxic., test for hepatit.B bef.init.ther.,
       3000636-001: 30, R521,81      zolam/ pimozide/ triazolam, ergot derivat.or zalcitabine, concom.St   imp.ren.funct., concom./ rec. nephrotox.meds., eval.poss.cause of
       Dosage: Init.ther.by physic. exper.in HIV infect. managem. Adults:   John’s Wort, concom.voriconazole, sev.hepat.impairm., safety &   decr. creatin.clear.in uninfect.PrEP pts.and re-eval.risk-benef., recom.
       1 tab. once dly. Rifampicin decr. bld.lev.of dolutegravir & supplement.  effic.in pts.less than 18 yrs.not est., congenit.galactosaem./gluc.&   concom.atazanavir be admin.with ritonavir, concom.didanosine &
       dos.of dolutegravir poss.reqd.  galact.malabsorpt./lactase defic.syndr.  discont.if advers. effs. develop, monit.BMD in pts.with patholog.
       Contraindications: Imp.ren.funct, pregn.& lactat., women of child-  Side effects: Lactic.acidos.& sev.hepatomegaly with steatos.incl.  bone fract.hist./at risk of osteopen., pts.to report joint ache/pain/
       bear.age not using highly effect. contracept., concom.adefovir dipiv-  fatal.with maj.of cases being women, sev.ac.exacerbat.of hepatit.B   stiffn. & diffic.movem.as osteonecros. poss., elderly, CV risk assessm.
       oxil/ dofetilide/ pilsicainide/didanosine/metformin, pts. &lt; 18 yrs.,   aft.discont., ren. impairm.incl.ac.ren.fail.& Fanconi syndr., ser. psych.  in pts.with evid. of lipodystroph., immune reconstitut. inflammat. syn-
       mod.to sev.hepat.impairm.     sympts.incl.sev.depress./ suicid.ideat./ delus. & pyschos.-like behav.,   dr., PrEP only as part of comprehens.prevent. strategy that incl.other.
       Side effects: Lamivudine: Freq: Hyperlactataem., arthralg., musc.  CNS sympts.incl. hallucinat./abnorm.think.& depersonalisat.which   prevent.meas., PrEP only in indiv. confirm.HIV-neg.as Tencitab alone
       disords., fatig., malaise, fev., headache, insomn., N&V, upper abdom.   gen. improv.with cont.ther., convuls., pancreatit., rash, allerg.reacts.,   does not constit.a compl.treatm.regim.for HIV-1, eval. seronegat.in-
       pain/ cramps, diarrh., rash, alopec. Less freq: Lactic acidos., lipod-  gynaecomast., GI disturbs., body fat redistribut./accumulat., weight   div.for curr./rec. S&S consist.with ac. vir infect. & enquire regard.
       ystrophy, neutropen., anaem., thrombocytopen., pancreatit., elev.ser.   gain/-loss, appetite incr., abnorm.co-ordinat., atax., hypoaesthes.,   poss expos.events in last mnth,if clinic.sympts.consist.with ac.vir.
       amylase, periph.neuropathy, late onset neurologic. disords. in childr.  paraesthes., periph.neuropathy, speech disord., abnorm.vis., tinnit.,   infect. pres.& recent vir.expos.suspect.delay start.PrEP for at least
       expos.in utero, rhabdomyolys., decr. BMD, osteopen., fract., trans.  palpitat., tachycard., asthma, URTI, GI disturbs., hepatit., hepat.fail.,   1 mnth & reconfirm HIV-1 status., rep.HIV-1 screen.at least every 3
       rises in AST/ ALT. Freq.unknown: Pure red cell aplas. Tenofovir   skin rash, incr.swell., erythema multiforme, Stev.-John.syndr., alo-  mnths.dur.PrEP treatm., monit. pts.on ther.utilis.a triple nucleoside-
       DF: Freq: Abdom.pain, anorex., dyspeps., flatul., asthen., dizzin.,   pec., skin exfoliat., urticar., nail disords., skin discolourat., acne, ec-  only regim.caref.for early virolog.fail./resist., lact.intol.
       hypophosphataem., ren.insuffic., ac.ren.fail., proxim. tubulopathy,   zema, folliculos., seborrh., photoallerg. dermatit., arthralg., myalg.,   Drug interactions: Ser.conc.incr.with concom. drugs elimin.by
       proteinur., incr.creatin., ac. tubul.necros., nephrogen.diabet.insipid.,   myopathy, impot., incr./decr.libido, fatig., asthen., hot flushes, ma-  act.tubul.secret., ser.conc.incr.by agents decr.ren.funct., atazanavir
       Fanconi syndr., polyur., interstit.nephrit. Less freq: Incr. amylase,   laise, influenza-like sympts., pain, neutropen., anaem., thrombocyto-  & lopinavir /ritonavir incr.tenofovir conc., AUC & C min of atazanavir
       pancreatit., lactic acidos., allerg.react., incr. ALT/AST/gamma GT,   pen., pure red cell aplas., cough, nas.sympts., rhabdomyolys., hyper-  decr., C max & AUC of didanosine incr.
       hepatit., rhabdomyolys., musc. weakn., osteomalac., myopathy.   triglyceridaem., hypercholesterolaem., insul. resist., hyperglycaem.,
       Freq.unknown: Dyspn., Dolutegravir: Freq: Fatig., headache, diz-  hyperlactataem., inflamm. react.to asymptomat./resid.infects.in sev.  TENEMINE, Mylan [P/S]
       zin., abnorm.dreams, insomn. , naus., diarrh., rash, prurit. Less freq:   immune defic.when init.ther., osteonecros., hypophosphataem.,   Tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page315.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page311.html">311</a>&nbsp;&nbsp;&nbsp;<a href="page312.html">312</a>&nbsp;&nbsp;&nbsp;<a href="page313.html">313</a>&nbsp;&nbsp;&nbsp;<a href="page314.html">314</a>&nbsp;&nbsp;&nbsp;<a href="page315.html">315</a>&nbsp;&nbsp;&nbsp;<a href="page316.html">316</a>&nbsp;&nbsp;&nbsp;<a href="page317.html">317</a>&nbsp;&nbsp;&nbsp;<a href="page318.html">318</a>&nbsp;&nbsp;&nbsp;<a href="page319.html">319</a>&nbsp;&nbsp;&nbsp;<a href="page320.html">320</a>&nbsp;&nbsp;&nbsp;<a href="page321.html">321</a>
             </td>
             <td width="35%"><a href="page317.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page317.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
